Biopharmaceuticals

Malaysian Healthcare Group Posts Triple Net Profit on Debt Reduction Strategy

Pharmaniaga's quarterly earnings surge reflects aggressive deleveraging and a landmark insulin contract that positions the firm for biopharmaceutical expansion across Southeast Asia